Published data from literature show a two-to four-fold increase in the incidence of JIDDM, in the Western hemisphere over the past decade (5% to 10-20%). WHO Expert Committee Technical Report Series No. 646 (1980) gives the risk of development of diabetes in the first two decades of life, in the sub-populations of Europe and North America, as 0.1% to 0.3%. In Japan, it is stated to be less than 0.02% ; in Tamil Nadu, India, we have calculated the risk to be less than 0.01%. The incidence of JIDDM amongst diabetics in urban Southern India has remained low and static in the last decade ; 0.8% and 0.84% in 1973 and 1981 respectively. This is so, despite the fact that infant and perinatal mortality rates over the past two decades have registered a sharp decline in our area. Childhood diabetes and its complications have not shown an uptrend in hospital admissions or infant mortality analysis. It is speculative that our ethnic group is lacks the genetic factor, Bf F, (which is strongly linked with HLA B,a and IDDM) and the increased association of S,. It remains to be elucidated whether the increased susceptibility to JIDDM of Caucasian children may be associated with a genetic factor or some other exogenous factor, Such as a nutritional factor or virus infection. A plea is made to exchange groups of diabetic children and study the "behavior" of their diabetes under different environments.
Background
We report a case-series of Ayurvedic treatment in seven COVID-19 positive patients with multiple comorbidities, categorized as high risk for poor outcome from SARS-CoV-2 infection. All of them recovered completely from their illness with resolution of symptoms following Ayurvedic treatment. The data was collected from patients treated during the early months of the COVID-19 pandemic (June 2020 to September 2020) at an out-patient Ayurvedic Clinic, Chennai, India.
Clinical Presentation
This is a retrospective case series from among the initial 247 COVID-19 patients out of whom 39% were found to be suffering from comorbidities. We have chosen seven of these patients who fulfilled the criteria for high-risk category, represented by multiple comorbidities that included cancer, chronic kidney disease (CKD), coronary artery disease (CAD), chronic obstructive pulmonary disease (COPD), diabetes mellitus (DM), hypertension and an elderly person over the age of 90 years.
Intervention
Classical Ayurvedic formulations for COVID -19 were chosen so as to avoid complicating co-morbid conditions and patients were maintained on a modified diet. All these high-risk patients were treated at an outpatient setting. The patients were under home quarantine and self-monitored their progress with daily follow up over the phone by the treating Ayurvedic physician.
Outcomes and Conclusions
The main outcome measure included resolution of symptoms and complete recovery from COVID-19 disease in all patients.
This case series demonstrates the scope of Ayurvedic interventions in management of high risk COVID-19 patients with severe comorbidities with successful outcome in an out-patient setting.
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.